Abstract
Currently available methods for assessing lung and airway inflammation are invasive, insensitive, or non-specificfor the inflammatory process and cannot quantify the total pulmonary inflammatory response accurately. Bronchoalveolar lavage remains the gold standard for detection of lung inflammation; however, its limitations include sampling errors and theinvasiveness of the procedure.Positron emission tomography is a non-invasive, highly sensitive imaging technique that can be used to quantify lung-specific inflammation and carries great potential as a biomarker that can be used to assess theefficacy of anti-inflammatory therapies on pulmonary inflammation. This chapter summarizes the clinical evidence supporting the use of PET imaging with [18F]fluorodeoxyglucose(FDG-PET) as a quantitative biomarker for neutrophilic pulmonary inflammation and some of the specific challenges for lung imaging with PET.
| Original language | English |
|---|---|
| Title of host publication | Trends on the Role of PET in Drug Development |
| Publisher | World Scientific Publishing Co. |
| Pages | 455-476 |
| Number of pages | 22 |
| ISBN (Electronic) | 9789814317740 |
| ISBN (Print) | 981431773X, 9789814317733 |
| DOIs | |
| State | Published - Jan 1 2012 |